The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids

AAPS Journal

Volumn 7, Issue 3, 2005, Pages

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Autoprotection; Cannabinoid receptors; Endocannabinoids; Fatty acid amide hydrolase inhibitors; Therapeutic strategies

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; ARACHIDONYL 2' CHLOROETHYLAMIDE; ARACHIDONYLCYCLOPROPYLAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR AFFECTING AGENT; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CODEINE; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; ICOSANOID; L 759633; L 759656; METHANANDAMIDE; MORPHINE; O 1812; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLOSTERISM; BIOSYNTHESIS; BLOOD BRAIN BARRIER; BRAIN INJURY; CANCER THERAPY; CARDIOVASCULAR DISEASE; CELL METABOLISM; CENTRAL NERVOUS SYSTEM DISEASE; CONCENTRATION RESPONSE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENTEROPATHY; EXCITOTOXICITY; HUMAN; IC 50; MENTAL DISEASE; MODULATION; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; RECEPTOR DENSITY; RECEPTOR UPREGULATION; REVIEW; TISSUE LEVEL; ANIMAL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; INFLAMMATION; METABOLISM; METHODOLOGY; NEOPLASM; NEUROLOGIC DISEASE; PHYSIOLOGY; TISSUE DISTRIBUTION;

ANIMALS; DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; HUMANS; INFLAMMATION; NEOPLASMS; NERVOUS SYSTEM DISEASES; RECEPTORS, CANNABINOID; TISSUE DISTRIBUTION;

EID: 33644804271     PISSN: 15221059     EISSN: 15221059     Source Type: Journal    
DOI: 10.1208/aapsj070364     Document Type: Review

References (219)

1. Howlett AC, Barth F, Bonner TI, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54:161-202. PubMed DOI: 10.1124/pr.54,2.161
2. Pertwee RG. Pharmacological actions of cannabinoids. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005;168:1-51.
3. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346:561-564. : 10.1038/346561a0
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 1993;365:61-65. ; 10.1038/365061a0
5. Pertwee RG. Pharmacology of cannabinoid receptor ligands. Curr Med Chem. 1999;6:635-664.
6. 1 receptors. Life Sci. 2005;76:1307-1324. : 10.1016/j.lfs.2004.10.025
7. Pertwee RG. Novel pharmacological targets for cannabinoids. Curr Neuropharmacol. 2004;2:9-29. : 10,2174/1570159043476927
8. 1 receptor. Mol Pharmacol. In press.
9. Bradshaw HB Walker JM The expanding field of cannabimimetic and related lipid mediators Br J Pharmacol. 2005;144:459-465. : 10.1038/sj.bjp.0706093
10. 1 receptor. Biochem Pharmacol. 2005; 69:169-178. : 10.1016/j.bcp.2004.08.033
11. Cabral GA, Staab A. Effects on the immune system. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005;168:385-423.
12. Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005;168:327-365.
13. Vaughan CW, Christie MJ, Retrogade signalling by endocannaboids, In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacology, Heidelberg, Germany: Springer-Verlag; 2005;168:367-383.
14. Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharmacol. 2004; 141:1118-1130. : 10.1038/sj,bjp.0705711
15. Baker CL, McDougall JJ. The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) act on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol. 2004;142:1361-1367. : 10,1038/sj,bjp,0705902
16. Di Marzo V, De Petrocellis L, Bisogno T. The, biosynthesis, fate and pharmacological properties of endocannabinoids. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimetal Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005;168:147-185.
17. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J. 2000;351:817-824. : 10,1042/0264-6021:3510817
18. 1 cannabinoid receptors. Br J Pharmacol. 2004; 141:253-262. : 10.1038/sj.bjp.0705607
19. 1 receptor. J Pharmacol Exp Ther. 2002;301:1020-1024. : 10.1124/jpet.301.3.1020
20. Cravatt BF, Lichtman AH. The endogenous cannabinoid system and its role in nociceptive behaviour, J Neurobiol, 2004;61:149-160. : 10.1002/neu.20080
21. Hillard CJ Jarrahian A Cellular accumalation of anandamide consensus and controversy Br J Pharmacol, 2003;140:802-808. : 10.1038/sj.bjp.0705468
22. Ueda N. Endocannabinoid hydrolases. Prostaglandins Other Lipid Mediat. 2002;68-9:521-534. DOI: 10,1016/S0090-6980(02)00053-9
23. Ho W-SV, Hillard CJ. Modulators of endocannabinoid enzymic hydrolysis and membrane transport. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacology. Heidelberg, Germany: Springer-Verlag; 2005;168:187-207.
24. Gulyas AI, Cravatt BF, Bracey MH, et al. Segregation of 2 endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci. 2004;20:441-458. : 10.1111/j.1460-9568.2004.03428.x
25. Ueda N, Yamanaka K, Yamamoto S. Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem. 2001;276:35552-35557. : 10.1074/jbc.M106261200
26. Lo Verme J, Gaetani S, Fu J, Oveisi F, Burton K, Piomelli D. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci. 2005;62:708-716. : 10,1007/s00018-004-4494-0
27. Fegley D, Gaetani S, Duranti A, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther. 2005; 313:352-358 : 10,1124/jpet.104.078980
28. Kozak KR, Marnett LJ. Oxidative metabolism of endocannabinoids, Prostaglandis Leukot Essent Fatty Acids. 2002;66:211-220. : 10.1054/plef.2001.0359
29. Saario SM, Savinainen JR, Laitinen JT Jarvinen T, Niemi R. Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol. 2004;67:1381-1387. : 10,1016/j.bcp.2003.12.003
30. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol. 2004;66:1260-1264. : 10.1124/mol.104.002071
31. Fezza F, Bisogno T, Minassi A, Appendino G, Mechoulam R, Di Marzo V. Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett. 2002:513:294-298. : 10.1016/S0014-5793(02)02341-4
32. De Petrocellis L, Davis JB, Di Marzo V. Palmitoylethanolamide enhances anandamide stimulation of human vanilloid VR1 receptors. FEBS Lett. 2001;506:253-256.
33. Sheskin T, Hanus L, Slager J, Vogel Z, Mechoulam R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J Med Chem. 1997;40:659-667. : 10.1021/jm960752x
34. Fernando SR, Pertwee RG. Evidence that methyl arachidonyl fluorophosphonate is an irreversible cannabinoid receptor antagonist. Br J Pharmacol. 1997;121:1716-1720. PubMed
35. 1 receptors. Br J Pharmacol. 2003:140:1451-1459. : 10.1038/sj.bjp.0705577
36. Nithipatikom K, Endsley MP, Isbell MA, et al. 2-Arachidonoyglycerol: a novel inhibitor of androgen-independent prostate cancer cell invasion. Cancer Res. 2004;64:8826-8830. PubMed
37. Kathuria S, Gaetani S, Fegley D, et al. Modulation of anxiety through blockade of anandamide hydrolysis, Nat Med. 2003;9:76-81. : 10.1038/nm803
38. Lichtman AH, Leung D, Shelton CC, et al. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther. 2004;311:441-448. : 10.1124/jpet.104.069401
39. Huang SM, Bisogno T, Petros TJ, et al. Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem. 2001;276:42639-42644. : 10,1074/jbc.M107351200
40. Bisogno T, Melck D, De Petrocellis L, et al. Arachidonoylserotonin and other novel inhibitor of fatty acid amide hydrolase. Biochem Biophys Res Commun. 1998;248:515-522. : 10.1006/bbrc.1998.8874
41. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology. 2003;125:677-687. : 10.1016/S0016-5085(03)00881-3
42. Jonsson K-O, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ. Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol. 2001;133:1263-1275. : 10.1038/sj.bjp.0704199
43. Khanolkar AD, Abadji V, Lin S, et al. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem. 1996;39:4515-4519. : 10.1021/jm960152y
44. Beltramo M, Stella N, Calignano A, Lin SY, Makriyannis A, Piomelli D, Functional role of high-affinity anandamide transport, as revealed by selective inhibition, Science 1997;277:1094-1097. : 10,1126/science.277.5329.1094
45. Jarrahian A, Manna S; Edgemond WS, Campbell WB, Hillard CJ. Structure-activity relationship among N-arachidonylethanolamine (anandamide) head group analogues for the anandamide transporter. J Neurochem. 2000;74:2597-2606.
46. Zygmunt PM, Chuang H, Movahed P, Julius D, Högesätt ED. The anandamide transport inhibitor AM404 activates vanilloid receptors. Eur J Pharmacol. 2000;396:39-42.
47. De Petrocellis L, Bisogno T, Davis JB, Pertwee RG, Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Lett. 2000;483:52-56. : 10,1016/S0014-5793(00)02082-2
48. Fowler CJ, Tiger G, Ligresti A, López-Rodríguez ML, Di Marzo V. Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis - a difficult issue to handle. Eur J Pharmacol, 2004;492:1-11. : 10.1016/j.ejphar.2004,03.048
49. Ortar G, Ligresti A, De Petrocellis L, Morera E, Di Marzo V. Novel Selective and metabolically stable inhibitor of anandamide cellular uptake. Biochem Pharmacol. 2003;65:1473-1481. : 10,1016/S0006-2952(03)00109-6
50. López-Rodríguez ML, Viso A, Ortega-Gutiérrez S, et al. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. Eur J Med Chem. 2003;38:403-412. : 10.1016/S0223-5234(03)00045-X
51. Ruiz-Llorente L, Ortega-Gutiérrez S, Viso A, et al. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol. 2004;141:457-467. : 10.1038/sj,bjp.0705628
52. 2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci. 2003;23:11136-11141. PubMed
53. Ramirez BG, Blázquez C, Gómez del Pulgar T, Guzmán N, de Ceballos ML. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blocked of microglial activation, J Neurosci. 2005;25:1904-1913. : 10.1523/JNEUROSCI.4540-04.2005
54. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108-2114. : 10.1038/sj.npp.1300558
55. Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665-1669. PubMed
56. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience. 2001; 103:9-15. : 10.1016/S0306-4522(00)00552-2
57. 1 receptors is increased in the anterior cingulate cortex in schizophrenia, Prog Neuropsychopharmacol Biol Psychiatry. 2004;28:355-360. : 10.1016 /j.pnpbp.2003.11.005
58. De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2:1-9. : 10,1186/1476-511X-2-5
59. 35S] GTPyS binding in the prefrontal cortex of depressed suicide victims, Mol Psychiatry. 2004; 9:184-190. : 10.1038/sj.mp.4001376
60. 1 receptors-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry. 2005;57:480-486. : 10,1016/j.biopsych.2004.11.033
61. 1 receptor binding and activation of GTP-binding proteins in the basal gangla of patients with Parkinson's syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001; 14:1827-1832. : 10.1046/j,0953-816x.2001.01812.x
62. Glass M, Faull R, Dragunow M. Loss of cannabinoid receptors in the substantia-nigra in Huntington's disease. Neurosci. 1993;56:523-527. : 10.1016/0306-4522(93)90352-G
63. Richfield EK, Herkenham M. Selected vulnerability in Huntington's desease: preferential loss of cannabinoid receptors in lateral globus pallidus. Ann Neurol, 1994;36:577-584. : 10,1002/ana.410360406
64. Schäbitz W-R, Giuffrida A, Berger C, et al. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke. 2002;33:2112-2114. : 10.1161/01.STR.0000023491.63693.18
65. Maccarrone M Valensise H, Bari M Lazzarin N Romanini C, Finazzi-Agricò A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet. 2000;355:1326-1329. : 10.1016/S0140-6736(00)02115-2
66. Maccarrone M, Bisogno T, Valensise H, et al. Low fatty acid amide hydrolase and high anandamide levels are associated with failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol Hum Reprod. 2002;8:188-195.
67. Wang Y, Liu Y, Ito Y, et al. Simultaneous measurement of anandamide and 2- arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: increase in endogenous cannabinoids in the sera of patients with endotoxic shock. Anal Biochem. 2001;294:73-82. : 10.1006/abio.2001.5015
68. 1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001;7:827-832. : 10.1038 /89953
69. Fernández-Rodriguez CM, Romero J, Petros TJ, et al. Circulating endogenous cannabinoid anandamide and portal, systemic and renal hemodynamics in cirrhosis, Liver Int.2004;24:477-483. : 10.1111/j.1478-3231.2004.0945.x
70. 2 in the liver, Gastroenterology, 2005;128:742-755. : 10.1053/j,gastro,2004.12.050
71. Steffens S, Veillard NR, Arnaud C, et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice, Nature. 2005;434:782-786. : 10.1038/nature03389
72. Maccarrone M, Attinà M, Cartoni A, Bari M, Finazzi-Agricò A. Gas chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy and tumoral human brain and human cells in culture.J Neurochem. 2001;76:594-601. : 10.1046/j.1471-4159.2001,00092.x
73. Petersen G, Moesgaard B, Schmid PC, et al. Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non-tumour brain tissue. J Neurochem, 2005;93:299-309. : 10.1111/j.1471-4159.2005.03013.x
74. Pagotto U, Marsicano G, Fezza F, et al. Normal human pituitary gland and pituitary adenomas express cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence for a direct role of cannabinoids on hormone modulation at the human pituitary level. J Clin Endocrinol Metab. 2001;86:2687-2696. : 10.1210/jc.86.2687
75. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H. Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res. 2005;65:1635-1641. PubMed
76. Motobe T Hashiguchi T, Uchimura T, et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. Shock: 2004;21:8-12. : 10.1097/01.SHK,0000094766.36694
77. Baker D. Pryce G, Croxford JL, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15:300-302. PubMed
78. 1, receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41:195-202. : 10.1002/syn.1075
79. 2 receptor agonist suppresses the murine model of experimental autoimmune uveitis. Invest Ophthalmol Vis Sci. 2004,45:552. : 10.1167/iovs.03-0749
80. G93A transgenic mice. J Neurochem. 2004;89:1555-1557. : 10.1111 /j.1471-4159.2004.02544.x
81. Benito C, Kim W-K, Chavarria I, et al. A glial endogenous cannabinoid system is upregulated in the brains of macaques with simian immunodeficiency virus-induced encephalitis. J Neurosci. 2005;25:2530-2536. : 10.1523/JNEUROSCI.3923-04.2005.
82. Adriani W, Caprioli A, Granstrem O, Carli M, Laviola G. The spontaneously hypertensive-rat as an animal model of ADHD: evidence for impulsive and non-impulsive subpopulations. Neurosci Biobehav Rev. 2003;27:639-651. : 10.1016/j.neubiorev.2003.08.007
83. Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 2000;4:1432-1438. : 10.1096/fj.14.10.1432
84. Gubellini P, Picconi B, Bari M, et al. Experiment parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J Nuerosci. 2002;22:6900-6907. PubMed
85. Maccarrone M, Gubellini P, Bari M, et al. Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism. J Neurochem. 2003;85:1018-1025. PubMed
86. Fernandez-Espejo E, Caraballo I, Rodriguez de Fonseca F, et al. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function. Neuropsychopharmacology. 2004;29:1134-1142. : 10.1038/sj.npp.1300407.
87. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci. 2003;18:1607-1614. : 10.1046/j.1460-9568.2003.02896.x
88. Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. 1991;547.267-274. : 10.1016/0006-8993(91)90970-7
89. 1 receptor mRNA levels in the caudate-putamen, Life Sci. 2000;66:485-494. : 10.1016/S0024-3205(99)00618-9
90. Mailleux P, Vanderhaeghen J-J. Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem. 1993;61:1705-1712. PubMed
91. 1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett, 1999;276:71-74. : 10.1016/S0304-3940(99)00762-4
92. McCaw EA, Hu H, Gomez GT, Hebb ALO, Kelly MEM, Denovan-Wright EM. Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's desease transgenic mice. Eur J Biochem. 2004:271:4909-4920. : 10.1111/j.1432-1033.2004.04460.x
93. Page KJ, Besret L, Jain M, Monaghan EM, Dunnett SB, Everitt BJ, Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and μ-opioid receptor binding in the basal ganglia. Exp Brain Res. 2000;130:142-150. : 10,1007/s002210050016
94. Lastres-Becker I, Fezza F, Cebeira M, et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease. Neuroreport. 2001;12:2125-2129. : 10.1097/00001756-200107200-00017
95. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport. 2004;15:2375-2379. : 10.1097/00001756-200410250-00015
96. Lastres-Becker I, Hansen HH, Berrendero F, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse. 2002;44:23-35. : 10.1002/syn.10054
97. 1 receptors in the basal ganglia of transgenic model of Huntington's disease. Brain Res. 2002;929:236-242. : 10.1016 /S0006-8993(01)03403-5
98. Walker JM, Huang SM, Strangman NM, Tsou K Sañudo-Peña MC. Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci USA. 1999;96:12198-12203. : 10.1073/pnas.96.21.12198
99. Lim G, Sung B, Ji R-R, Mao J. Upregulation of spinal cannabinoid-1-receptors following nerve injury enhances the effects of Win 55,212-2 on neuropathic pain behaviors in rats. Pain. 2003;105:275-283. : 10,1016/S0304-3959(03)00242-2
100. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci. 2003;17:2750-2754. : 10.1046/j.1460-9568.2003.02704x
101. Dinis P, Charrua A, Avelino A, et al. Anandamide-evoked activation to vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nocciceptive transmission to spinal dorsal horn neurons in crystitis. J Neurosci, 2004;24:11253-11263. : 10.1523/JNEUROSCI.2657-04.2004
102. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822-825. : 10.1038/35071088
103. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Phermacol. 2003;63:908-914. : 10.1124/mol.63.4.908
104. Maccarrone M, Fride E, Bisogno T, et al. Up-regulation of the endocannabinoid system in the uterus of leptin knockout (ob/ob) mice and implications for fertility, Mol Hum Reprod. 2005;11:21-28. : 10.1093/molehr/gah130
105. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachiodonoyl glycerol, Br J Pharmacol. 2002; 136:550-557. : 10.1038/sj.bjp.0704767
106. Hill MN, Patel S, Carrier EJ, et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress, Neuropsychopharmacology. 2005;30:508-515. : 10.1038/sj.npp.1300601
107. Patel S, Roelke CT, Rademacher DJ, Hillard CJ, Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. Eur J Neurosci. 2005;21:1057-1069. : 10.1111/j.1460-9568.2005,03916.x
108. Marsicano G, Wotjak CT, Azad SC, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature. 2002;418:530-534. : 10.1038/nature00839
109. 1 receptor protien expression in the rat hippocampus and entorhinal, perirhinal, postrhinal and temporal cortices: regional varitions and age-related changes. Brain Res. 2003;979:235-239. : 10.16/S0006-8993(03)02872-5
110. Sparling PB, Giuffrida A, Piomelli D, Rosskopf L, Dietrich A. Exercise activates the endocannabinoid system. Neuroreport. 2003;14:2209-2211. : 10.1097/00001756-200312020-00015
111. Bátkai S, Pacher P. Osei-Hyiaman D, et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation. 2004;110:1996-2002. : 10.1161/01.CIR.0000143230.23252.D2
112. Domenicali M, Ros J, Fernández-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilliod receptors. Gut. 2005;54:522-527. : 10.1136/gut.2004.051599
113. Varga K, Wagner JA, Bridgen DT, Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension, FASEB J. 1998;12:1035-1044. PubMed
114. Liu J, Bátkai S, Pacher P, et al. Lipopolysaccharide anandamide synthesis in macrophages via CD14/MAPK/phosphoinositide 3-kinase/NF-KB independently of platelet-activating factor. J Biol Chem, 2003;278:45034-45039. : 10.1074/jbc.M306062200
115. Maccarrone M, De Petrocellis L, Bari M, et al. Lipopolysaccharide downregulates fatty acid amide hydrolase expression and increases anandamide levels in human peripheral lymphocytes. Arch Biochem Biophys, 2001;393:321-328. : 10.1006/abbi.2001.2500
116. Wagner JA, Hu K, Bauersachs J, et al. Endogenous cannabinoids mediate hypotnsion after experimental myocardial infarction. J Am Coll Cardiol, 2001;38:2048-2054. : 10.1016/S0735-1097(01)01671-0
117. 1 -receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134:563-570. : 10.1038/sj.bjp.0704293
118. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest. 2004;113:1202-1209. : 10.1172/JCI200419465
119. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology. 2003;125:765-774. ; 10.1016/S0016-5085(03)00892-8
120. McVey DC, Schmid PC, Schmid HHO, Vigna SR. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther. 2003;304:713-722. : 10.1124/jpet.102.043893
121. Mascolo N, Izzo AA, Ligresti A, et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J, 2002;16:U131-U51.
122. 1 cannabinoid receptor induction in experimental stroke. Ann Neurol. 2000;48:257-261. : 10,1002/1531-8249(200008)48:2<257 AID-ANA18>3.0.CO_2-P
123. 1 cannabinoid receptor blockade is protective during transient, focal cerebral ischemia. Neuroscience, 2004;129:743-750. : 10.1016/j.neuroscience.2004.08.044
124. Kurabayashi M, Takeyoshi I, Yoshinari D, Matsumoto K, Maruyama I, Morishita Y. 2-Arachidonoylglycerol increases in ischemia-reperfusion injury of the rat liver. J Invest Surg, 2005;18:25-31. PubMed
125. Hansen HH, Schmid PC, Bittigau P, et al. Anandamide, but not 2-arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem, 2001;78:1415-1427. : 10.1046/j.1471-4159.2001.00542.x
126. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury, Nature. 2001;413:527-531. : 10.1038/35097089
127. Sugiura T, Yoshinaga N, Kondo S, Waku K, Ishima Y. Generation of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, in picrotoxinin-administered rat brain. Biochem Biophys Res Commun. 2000;271:654-658. : 10.1006/bbrc.2000.2686
128. 1 cannabinoid receptors and on-demand defense against excitotoxicity. Science. 2003;302:84-88. : 10.1126/science,1088208
129. Chen K, Ratzliff A, Hilgenberg L, et al. Long-term plasticity of endocannabinoid signaling induced by developmental febrile seizures. Neuron. 2003;39:599-611. : 10.1016/S0896-6273(03)00499-9
130. Maccarrone M, Piccirilli S, Battista N, et al. Enhanced anandamide degrations is associated with neuronal apoptosis induced by the HIV-1 coat glycoprotein gp120 in the rat neocortex. J Neurochem. 2004;89:1293-1300. : 10.1111/j.1471-4159.2004.02430.x
131. 2 cannabinoid receptor. Cancer Res. 2001;61:5784-5789. PubMed
132. Burstein SH, Rossetti RG, Yagen B, Zurier RB. Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat. 2000;61:29-41. : 10.1016/S0090-6980(00)00053-8
133. de Lago E, Ligresti A, Ortar G, et al. In vivo pharmacological actions of 2 novel inhibitors of anandamide cellular uptake. Eur J Pharmacol. 2004;484:249-257. : 10.1016/j.ejphar.2003.11.027
134. Burstein SH, Huang SM, Petros TJ, Rossetti RG, Walker JM, Zurier RB. Regulation of anandamide tissue levels by N-arachidonylglycine. Biochem Pharmacol. 2002;64:1147-1150. : 10.1016/S0006-2952(02)01301-1
135. Cravatt BF, Demarest K Partricelli MP et al. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 2001;98:9371-9376. : 10.1073/pnas.161191698
136. Lichtman AH, Shelton CC, Advani T, Cravatt BF. Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain. 2004;109:319-327. : 10.1016/j.pain.2004.01.022
137. Cravatt BF, Saghatelian A, Hawkins EG, Clement AB, Bracey MH, Lichtman AH. Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc Natl Acad Sci USA 2004:101:10821-10826. : 10.1073/pnas.0401292101
138. Martin BR, Lichtman AH. Cannabinoid transmission and pain perception. Neurobiol Dis, 1998;5:447-461. : 10.1006/nbdi.1998.0218.
139. Pertwee RG. Cannabinoid receptors and pain. Prog Neurobiol. 2001;63:569-611. ; 10,1016.S0301-0082(00)00031-9
140. Walker JM, Hohman AG. Cannabinoid mechanisms of pain suppression. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005;168:509-54.
141. Herzberg U, Eliav E, Bennett GJ, Kopin IJ. The analgesic effects of R(+)-WIN 55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett. 1997;221:157-160. : 10.1016/S0304-3940(96)13308-5
142. Edsall SA, Knapp RJ, Vanderah TW, Roeske WR, Consroe P, Yamamura HI. Antisense oligodeoxynucleotide treatment to the brain cannabinoid receptor inhibits antinociception. Neuroreport. 1996;7:593-596. PubMed
143. Richardson JD, Aanonsen L, Hargreaves KM, Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J Neurosci. 1998;18:451-457. PubMed
144. 1 receptors produces abnormal pain and elevates spinal dynorphin content in mice. Pain. 2002;100:203-209. : 10.1016/S0304-3959(02)00302-0
145. 1 receptors, Eur J Neurosci. 2000; 12:533-539. : 10.1046/j.1460-9568.2000.00929.x
146. 2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA, 2003;100:10529-10531. : 10.1073/pnas.1834309100
147. 1 receptor knockout mice. Science. 1999;283:401-404. : 10.1126 /science.283.5400.401
148. 1 receptor knockout mice. Proc Natl Acad Sci USA. 1999; 96:5780-5785. : 10.1073/pnas.96.10.5780
149. 2, a peripheral cannabinoid receptor. Proc Natl Acad Sci USA. 1999;96:14228-14233. : 10.1073/pnas.96.25.14228
150. 2 cannabinoid receptors are implicated in inflammatory pain. Pain. 2002;96:253-260. : 10.1016/S0304-3959(01)00454-7
151. Valenzano KJ, Tafesse L, Lee G, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology. 2005;48:658-672 : 10.1016/j.neuropharm.2004.12.008
152. 2 cannabinoid receptor-mediated peripheral antinociception. Pain. 2001;93:239-245. ; 10.1016/S0304-3959(01)00321-9.
153. 2 receptors suppresses spinal Fos protein expression and pain behavior in a rat model of inflammation. Neuroscience. 2003;119:747-757. : 10.1016/S0306-4522(03)00126-X
154. 2 cannabinoid receptors. Anesthesiology. 2003;99:955-960. : 10.1097/00000542-200310000-00031
155. 2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther. 2004; 308:446-453. : 10.1124/jpet.103.060079
156. 2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids, Proc Natl Acad Sci USA, 2005;102:3093-3098. : 10.1073/pnas.0409888102
157. Ross RA, Coutts AA, McFarlane SM, et al. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology. 2001;40:221-232. : 10.1016/S0028-3908(00)00135-0
158. Holt S, Comelli F, Costa B, Fowler CJ. Inhibitors of fatty acid amide hydrolase reduce carrageenan induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible : 10.1038/sj.bjp.0706348
159. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998;394:277-281. : 10.1038/28393
160. Beaulieu P, Bisogno T, Punwar S, et al. Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur J Pharmacol, 2000;396:85-92. : 10.1016/S0014-2999(00)00226-0
161. Notcutt W, Price M, Miller R, et al. Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 'N of 1' studies. Anaesthesia, 2004;59:440-452. : 10.1111/j.1365-2044.2004.03674.x
162. Noyes R, Brunk SF, Baram DA, Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol, 1975; 15:139-143. PubMed
163. Noyes R, Brunk SF, Avery DH, Canter A. Analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 1975;18:84-89. PubMed
164. Pertwee RG. Cannabinoids and multiple sclerosis, Pharmacol Ther. 2002;95:165-174. : 10,1016/S0163-7258(02)00255-3.
165. Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29. : 10.1191/0269215503cr581oa
166. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362:1517-1526. : 10.1016/S0140-6736(03)14738-1
167. Gauter B, Rukwied R, Konrad C. Cannabinoid agonists in the treatment of blepharospasm - a case report study. Neuroendocrinol Lett. 2004;25:45-48. PubMed
168. Brady CM, DasGupta R, Dalton C, Wiseman OJ, Berkley KJ, Fowler CJ, An Open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mlt Scler. 2004;10:425-433. : 10.1191/1352458504ms1063oa
169. Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomized double blind placebo controlled crossover trial. BMJ. 2004;329:253-257. : 10.1136/bmj.38149.566979.AE
170. 2 receptor, J Pharmacol Exp Ther, 2001;296:420-425. PubMed
171. 2 receptor inhibitors: identification of a lead and initial SAR studies, Bioorg Med Chem Lett. 2005;15:783-786. : 10.1016/j.bmcl.2004.11.007
172. 2 receptor. Symposium on cannabinoid receptors: pharmacological opportunities for obesity and inflamation: New York Academy of Sciences, 2004; Available at: http://www.nyas.orgbriefreps/main.asp?intSubsectionID=1406.
173. Costa B, Colleoni M, Trovato AE, Comelli F, Franke C, Giognoni G. Anandamide transport and hydrolysis as targets for the treatment of neuropathic pain: Effects of AM404 and URB597 in rats with chronic constriction injury of the sciatic nerve. 2005 Symposium on the Cannabinoids; June 24-27; Burlington, VT. Burlington, VT: International Cannabinoid Research Society.; 2005. 33.
174. Mestre L, Correa F, Arévalo-Martin A, et al. Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem. 2005:92:1327-1339. : 10.1111/j.1471-4159.2004.02979.x
175. Pryce G, Ahmed Z, Hankey DJR, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain, 2003;126:2191-2202. : 10.1093/brain/awg224
176. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404:84-87. : 10.1038/35003583
177. 2 receptors. Eur J Pharmacol. 2002; 439:83-92. : 10.1016/S0014-2999(02)01369-9
178. 9-tetrahydrocannabinol necessary for all its effects? J Pharm Pharmacol. 2003;55:1687-1694. : 10.1211/0022357022304
179. 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 1989; 23:73-81. : 10.1016/0162-5728(89)90075-1
180. Wirguin I, Mechoulam R, Breuer A, Schezen E, Weidenfeld J, Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology, 1994;28:209-214. : 10.1016/0162-3109(94)90056-6
181. Croxford JL, Miller SD. Immunoregulation of a vital model of multiple sclerosis using the synthetic cannabinoid R(+)WIN55,212. J Clin Invest. 2003;111:1231-1240. : 10.1172/JCI200317652
182. Arévalo-Martin N, Vela JM, Molina-Holgado E, Borrell J, Guaza C. Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci. 2003;23:2511-2516. PubMed
183. Vaney C, Heinzel-Gutenbrunner M, Jobin P, et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler. 2004; 10:417-424. : 10.1191/1352458504ms1048oa
184. Wade DT, Makela P, Robson P, House H, Bateman C, Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441. : 10.1191/1352458504ms1082oa
185. Killestein J, Hoogervorst ELJ, Reif M, et al. Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 2002;58:1404-1407 PubMed
186. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, Di Maarzo V. A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J. 2004;18:U320-U33.
187. Bifulco M, Laezza C, Portella G, et al. Control by the endogenous cannabinoid system of ras oncogene-dependent tumor growth. FASEB J. 2001;15:U100-U16.
188. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med. 2002;8:547-550. : 10.1038/nm0602-547
189. 1 receptor stimulation on tumor grow and metastic spreading: actions on signals involved in angiogenesis and metastasis, FASEB J. 2003;17:U458-U74.
190. Guzmán M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3:745-755. : 10.1038/nrc1188
191. Guzmán M. Effects on cell viability In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology. Heidelberg, Germany: Springer-Verlag; 2005:168:627-642.
192. Izzo AA, Coutts AA. Cannabinoids and the digestive tract. In: Pertwee RG, ed. Cannabinoids, Handbook of Experimental Pharmacolology, Heidelberg, Germany: Springer-Verlag; 2005; 168:573-598.
193. B inhibition. J Cereb Blood Flow Metab. 2005;25:477-484. : 10.1038/sj.jcbfm.9600047
194. 1 antagonist SR141716A in a rat Parkinson's model. Neurobiol Dis, 2004:16:377-385. : 10.1016 /j.nbd.2004.03.002
195. 1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiol Dis. 2005;18:591-601. : 10.1016 /j.nbd.2004.10.015.
196. Meschler JP, Howlett AC, Madras BK. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6- tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berl). 2001; 156:79-85. : 10.1007/s002130100728
197. 1 cannabinoid receptors in haemorrhagic shock. Nature. 1997;390:518-521. : 10.1038/37371
198. Kadoi Y, Hinohara H, Kunimoto F, Kuwano H, Saito S, Goto F. Effects of AM281, a cannabinoid antagonist, on systemic haemodynamics, internal carotid artery blood flow and mortality in septic schock in rats, Br J Anaesth. 2005;94:563-568. : 10.1093/bja/aei106
199. Robson PJ. Human studies of cannabinoids and medicinal cannabis in: Pertwee RG, ed. Cannabinoids, Handbook Exp Pharmacol. Heidelberg, Germany: Springer-Verlag; 2005:719-756.
200. Robson PJ, Guy GW. Clinical studies of cannabis-based medicines. In: Guy GW, Whittle BA, Robson PJ, eds. The Medicinal Uses of Cannabis and Cannabinoids. London, UK: Pharmaceutical Press; 2005:229-269.
201. Consroe P, Musty R, Rein J, Tillery W, Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 1997;38:44-48. PubMed
202. Ware MA, Adams H, Guy GW. The medicinal use of cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59:291-295. : 10.1111/j.1742-1241.2004.00271.x
203. 2 receptor partial agonist with antihyperalgesic and antiallodynic effects. J Pharmacol Exp Ther, 2004; 310:620-632 : 10.1124/jpet.103.062836
204. Rukwied R, Watkinson A, McGlone F, Dvorak M Cannabinoid agonist attenuate capsaicin-induced responses in human skin. Pain. 2003;102:283-288. : 10.1016/S0304-3959(02)00401-3
205. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine-induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res. 2003;52:238-245. PubMed
206. Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci, 2004;74:1317-1324.
207. Holdcroft A, Smith M, Jacklin A, et al. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 1997;52:483-488. : 10.1111/j.1365-2044.1997.139-az0132.x
208. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. In: Di Marzo V, ed. Cannabinoids. New York, NY: Kluwer Academic/Plenum Publisher; 2004:32-83.
209. Mendelson WB, Basile AS. The hypnotic actions of the fatty acid amide, oleamide. Neuropsychopharmacology. 2001;25:S36-S39. : 10.1016/S0893-133X(01)00341-4
210. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essen Fatty Acids. 2002-166:101-121. : 10.1054/plef.2001.0341
211. 1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol. 2003;15:91-119. : 10.1615/CritRevNeurobiol.v15.12.10
212. Lichtman AH, Martin BR. Cannabinoid tolerance and dependence, In; Pertwee RG, ed. Cannabinoids. Handbook of Experimental Pharmacolology. Heidelberg, Germany. Springer-Verlag: 2005;168-691-717.
213. De Vry J, Jentzsch KR, Kuhl E, Eckel G. Behavioral effects of cannabinoids show defferential sensitivity to cannabinoid receptor blockade and tolerance development. Behav Pharmacol. 2004;15:1-12. : 10.1097/00008877-200402000-00001
214. Paria BC, Dey SK. Ligand-receptor signaling with endocannabinoids in preimplantation embryo development and implantation. Chem Phys Lipids. 2000;108:211-220. : 10.1016/S0009-3084(00)00197-3
215. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet. 2005;365:1389-1397. : 10.1016/S0140-6736(05)66374-X
216. Idris AI, van't Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors: Nat Med. 2005;11:774-779. : 10.1038/nm1255
217. Brown AJ, Ueno S, Suen K, Dowell SJ, Wise A Molecular identifation of GPR55 as a third G protein-coupled receptor responsive to cannabinoid ligands. Symposium on the Cannabinoids; June 24-27; Burlington, VT. Burlington, VT: International Cannabinoid Research Society; 2005. 16.
218. Sjögren S, Ryberg E, Lindblom A, et al. A new receptor for cannabinoid ligands Symposium on the Cannabinoids; June 24-27, Burlington, VT. Burlington, VT: International Cannabinoid Research Society; 2005. 106.
219. Hohmann AG, Suplita RL, Bolton NM, et al. An endocannabinoid mechanism for stress-induced analgesia. Nature. 2005;435:1108-1112. : 10.1038/nature03658